| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Decrease in right of use assets | - | 149 |
| Net cash used in operating activities | -6,456 | -5,094 |
| Purchases of property and equipment | 12 | 0 |
| Net cash used in investing activities | -12 | 0 |
| Proceeds from atm sale of common stock, net of transaction costs | 154 | - |
| Proceeds from registered direct sale of common stock, net of transaction cost | 4,183 | - |
| Net cash provided by financing activities | 4,337 | - |
| Net decrease in cash and restricted cash | -2,131 | -5,094 |
| Cash and cash equivalents at beginning of period | 9,935 | - |
| Cash and cash equivalents at end of period | 7,804 | - |
Cocrystal Pharma, Inc. (COCP)
Cocrystal Pharma, Inc. (COCP)